Korean J Obstet Gynecol.  2004 Feb;47(2):258-263.

Development of Trans Attack Anticancer Gene Vaccine Interact in HPV Oncoprotein Expression Inhibition

• Lee HJ
• Lee SH
• Kim HJ
• Kim JH
• Lew YO
• Lee JO
• Kim YW
• Ahn WS
• Kim CK
• Lee JM
• Kim DH
• Namkoong S
• Kang KD

Abstract

OBJECTIVE
Adeno-associated virus Rep 78 protein is known to inhibit the promoter site of several onco-genes and viral gene, including the human papillomavirus type 16 E6 transforming genes. In this study, we investigated AAV Rep 78 mediated inhibition of HPV 16 E6 promotor activity.
METHODS
pcDNA3.1/V5/His-Topo vector, cloned by AAV mediated Rep 78, is transfected into cervical cancer cell line (Caski). After that, we confirmed HPV16 derived E6 expression and cell growth inhibition.
RESULTS
Transfection rate of Rep78 GFP-vector, approximately from 30 to 60 per-cent, is highly expressed at first day. But E6 expression is lower at this day. The growth of CaSki and HeLa cervical cancer cell lines was inhibited by Rep78 (p<0.05). But, the other cervical cancer cells were unaffected by Rep78 transfection.
CONCLUSION
In spite of the high Rep78 transfection efficiency and expression rate, we could not show the cervical cancer cell growth inhibition. In our data, long term expression of Rep78 strategy is needed for cervical carcinoma gene therapy using adeno-associated virus vector.

Keyword

Rep78; AAV (adeno-associated virus); E6 oncoprotein; HPV

MeSH Terms

Cell Line
Clone Cells
Dependovirus
Genes, Viral
Genetic Therapy
Human papillomavirus 16
Humans
Oncogenes
Transfection
Uterine Cervical Neoplasms